6533b85afe1ef96bd12b8b80
RESEARCH PRODUCT
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients
Maurizio MasulloA. CapacciRoberto GiacomelliFabio FischettiMariateresa CirilloGiuliana GugginoGiovanni BiasiLorenzo DagnaManuela Di FrancoMarco GhiniMaurizio CutoloDaniele SantilliSara BonazzaF. MozzaniCarlo SalvaraniElisa GremeseIlenia RiccucciGianluigi BajocchiAlberto BatticciottoLaura BazzichiGiulio CavalliMarco Di CarloFlorenzo IannoneStefano BarbagliSonia FarahSerena GuiducciRoberto GerliMarcello GovoniFrancesca NacciFrancesco CarubbiPiercarlo Sarzi-puttiniMario BentivegnaBianca Maria PolizziLuigi SinigagliaFabiola AtzeniValeria GiorgiChiara GioiaFausto Salaffisubject
MalePercentileSettore MED/16 - REUMATOLOGIAFibromyalgiaCross-sectional studyseverityDiseaseSeverity of Illness IndexEconomica0302 clinical medicinemodifiedInterquartile rangeRetrospective StudieFibromyalgiaSurveys and QuestionnairesSurveys and QuestionnairePharmacology (medical)030212 general & internal medicinecut-off pointsPain MeasurementFibromyalgia Assessment Status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severity; Cross-Sectional Studies; Female; Fibromyalgia; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Pain Measurement; Prognosis; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of LifeIncidencerevised Fibromyalgia Impact Questionnairecut-off points; fibromyalgia; Fibromyalgia Assessment Status; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severityMiddle AgedPrognosisDistressItalyFemalefibromyalgiaFibromyalgia Assessment StatusHumanmedicine.medical_specialtyPrognosiRevised Fibromyalgia Impact QuestionnaireFollow-Up Studie03 medical and health sciencesRheumatologyInternal medicineSeverity of illnesscut-off pointmedicineHumansRetrospective Studies030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industrymedicine.diseaseFibromyalgia Assessment StatuCross-Sectional StudiesFibromyalgia; severity; cut-off points; revised Fibromyalgia Impact Questionnaire; modified; Fibromyalgia Assessment Status; polysymptomatic distress scalepolysymptomatic distress scalefibromyalgia assessment status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised fibromyalgia impact questionnaire; severityQuality of LifebusinessFollow-Up Studiesdescription
Abstract Objective To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity. Methods Consecutive FM patients were evaluated with the three clinimetric indices, and each patient was required to answer the anchor question: ‘In general, would you say your health is 1 = very good, 2 = good, 3 = fair, 4 = poor, or 5 = very poor?’—which represented the external criterion. Cut-off points were established through the interquartile reconciliation approach. Results The study sample consisted of 2181 women (93.2%) and 158 men (6.8%), with a mean age of 51.9 (11.5) years, and mean disease duration was 7.3 (6.9) years. The overall median FIQR, FAS 2019 mod and PDS scores (25th–75th percentiles) were respectively 61.16 (41.16–77.00), 27.00 (19.00–32.00) and 19.0 (13.00–24.00). Reconciliation of the mean 75th and 25th percentiles of adjacent categories defined the severity states for FIQR: 0–23 for remission, 24–40 for mild disease, 41–63 for moderate disease, 64–82 for severe disease and >83 for very severe disease; FAS 2019 mod: 0–12 for remission, 13–20 for mild disease, 21–28 for moderate disease, 29–33 for severe disease and >33 for very severe disease; PDS: 0–5 for remission, 6–15 for mild disease, 16–20 for moderate disease, 21–25 for severe disease and >25 for very severe disease. Conclusions Disease severity cut-offs can represent an important improvement in interpreting FM.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-01 |